Role of dipA and pilD in Francisella tularensis Susceptibility to Resazurin

Kendall Souder 1*, Emma J. Beatty 1, Siena C. McGovern 1, Michael Whaby 1*, Emily Young 1, Jacob Pancake 1, Daron Weekley 1, Justin Rice 1, Donald A. Primerano 2*, James Denvir 2, Joseph Horzempa 1* and Deanna M. Schmitt 1*.

1 Department of Biomedical Sciences, West Liberty University, West Liberty, WV 26074, USA; kssouder@westliberty.edu (K.S.); ejbeatty@westliberty.edu (E.B.); scmcgovern@westliberty.edu (S.C.M.); whaby@musc.edu (M.W.); emily.young@westliberty.edu (E.Y.); jppancake2121@gmail.com (J.P.); dmweekley@westliberty.edu (D.W.); jcrice1@westliberty.edu (J.R.); joseph.horzempa@westliberty.edu (J.H.)
2 Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA; primeran@marshall.edu (D.A.P.); donvir@marshall.edu (J.D.)
* Correspondence: deanna.schmitt@westliberty.edu; Tel.: +1-304-336-8576

Abstract: The phenoxazine dye resazurin exhibits bactericidal activity against the Gram-negative pathogens Francisella tularensis and Neisseria gonorrhoeae. One resazurin derivative, resorufin pentyl ether, significantly reduces vaginal colonization by Neisseria gonorrhoeae in a mouse model of infection. The narrow spectrum of bacteria susceptible to resazurin and its derivatives suggests these compounds have a novel mode of action. To identify potential targets of resazurin and mechanisms of resistance, we isolated mutants of F. tularensis subsp. holarctica live vaccine strain (LVS) exhibiting reduced susceptibility to resazurin and performed whole genome sequencing. The genes pilD (FTL_0959) and dipA (FTL_1306) were mutated in half of the 46 resazurin-resistant (RZR) strains sequenced. Complementation of select RZR LVS isolates with wild-type dipA or pilD partially restored sensitivity to resazurin. To further characterize the role of dipA and pilD in resazurin susceptibility, a dipA deletion mutant, ΔdipA, and pilD disruption mutant, FTL_0959d, were generated. Both mutants were less sensitive to killing by resazurin compared to wild-type LVS with phenotypes similar to the spontaneous resazurin-resistant mutants. This study identified a novel role for two genes dipA and pilD in F. tularensis susceptibility to resazurin.

Keywords: Francisella tularensis; resazurin; DipA; PilD; tularemia; antimicrobial; antibiotic; resistance

1. Introduction

The Centers for Disease Control and Prevention (CDC) estimates that there are nearly three million new cases of antibiotic resistant bacterial infections annually, resulting in 35,000 deaths and billions of dollars in health care costs in the United States [1]. The rise in antibiotic resistance has been attributed to over-prescription and improper use of commonplace antibiotics [2]. Despite the clinical threat posed by increasing antibiotic resistance, the development of new antibiotics has significantly slowed due to decreased profitability [3]. While there are over 40 antimicrobial agents in clinical trials, most belong to existing classes of antibiotics such as beta lactams and beta-lactamase inhibitors, tetracyclines, and aminoglycosides [4]. Each of these classes of antibiotics targets similar bacterial processes including cell wall synthesis and protein synthesis. The development of bacterial resistance against these new drugs in the future is likely since there is already selective pressure from current antibiotics. Therefore, new antibiotic targets should be explored to minimize the emergence of resistance and provide effective alternatives.

Phenoxazine-based compounds have been shown to have antimicrobial activity [5,6]. Actinomycin D, the most well-known phenoxazine-containing antibiotic, suppresses the growth of various Gram-positive and Gram-negative bacteria as well as Mycobacterium tu-
berculosis [7]. Other actinomycins, neo-actinomycins A and B, exhibit moderate antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) strains [8]. We previously showed the phenoxazine dye resazurin inhibits growth of the Gram-negative human pathogens Neisseria gonorrhoeae and Francisella tularensis [9,10]. Resorufin pentyl ether, an analog of resazurin, significantly reduces vaginal colonization by N. gonorrhoeae in a mouse model of infection [10]. However, the mechanism by which resazurin kills F. tularensis and N. gonorrhoeae has not been defined. Based on its structural similarity to other phenoxazine compounds, resazurin may function as a DNA intercalating agent [5]. Unlike other phenoxazine compounds, resazurin is non-toxic to eukaryotic cells, and its bactericidal activity is limited to only two Gram-negative bacterial species suggesting a novel mechanism of action [5,6,9].

In this study, we sought to identify F. tularensis genetic determinants involved in susceptibility to resazurin in hopes of elucidating the mode of action of this compound.

2. Results

2.1. Isolation of Resazurin-Resistant F. tularensis LVS Mutants

A common strategy bacteria employ to develop antimicrobial resistance is by mutating gene(s) associated with the mechanism of action of the antibiotic. Therefore, to identify potential targets of resazurin, we selected for mutants of F. tularensis LVS that were capable of growing in the presence of 22 µg/mL of resazurin. This concentration of resazurin is twenty-fold higher than the previously determined MIC of resazurin for F. tularensis LVS [9]. The genomes of forty-six spontaneous resazurin-resistant (RZR) mutants were sequenced and compared to wild-type LVS to identify genetic variants. Nonsynonymous mutations were identified in ten different protein-coding F. tularensis LVS genes with approximately 50% of the isolates possessing mutations in FTL_1306 (dipA) and FTL_0959 (pilD) (Table 1). The same pilD variant was observed in twenty-two of the RZR LVS isolates involving a single base pair substitution leading to a premature stop codon at position 187 of the protein sequence (Table 2). Fifteen different coding mutations were characterized in dipA that included single base pair substitutions, insertions, and deletions with many resulting in nonsense mutations (Table 2). Of note, one RZR LVS isolate, RZR46, contained a deletion of a single thymine residue at Position 2 in dipA resulting in loss of the start codon (Table 2). Western blot analysis confirmed this mutation abolished expression of DipA protein in RZR46 (data not shown). These data suggest the genes dipA and pilD play a role in F. tularensis LVS susceptibility to resazurin.

| F. tularensis Gene Name | Number of Resazurin-Resistant Isolates Containing Gene Mutation |
|------------------------|---------------------------------------------------------------|
| FTL_1306 (dipA)        | 24                                                            |
| FTL_0959 (pilD)        | 22                                                            |
| FTL_1666               | 5                                                             |
| FTL_0073               | 4                                                             |
| FTL_0358               | 2                                                             |
| FTL_0610               | 2                                                             |
| FTL_0132               | 1                                                             |
| FTL_0315               | 1                                                             |
| FTL_1634               | 1                                                             |
| FTL_1654               | 1                                                             |
Table 2. Description of dipA and pilD mutations found in sequenced resazurin-resistant (Rzr) F. tularensis LVS isolates.

| Mutation Type         | Nucleotide Change           | Protein Change |
|-----------------------|-----------------------------|----------------|
| DipA                  |                             |                |
| Frameshift and start lost  | 1_19delATGAAAGCTAATTATAAA   | Start lost     |
| Frameshift and start lost  | 2delT                       | Start lost     |
| Stop gained           | 169G > T                    | Glu57 *        |
| Stop gained           | 211G > T                    | Glu71 *        |
| Stop gained           | 268G > T                    | Glu89 *        |
| Stop gained           | 310G > T                    | Glu104 *       |
| Frameshift and stop gained | 342_346delGGTAG             | Lys114Xfs6 *   |
| Frameshift and stop gained | 349_350delCA                | Gln117Lysfs6 * |
| Frameshift and stop gained | 350_353delAAA               | Lys119Valfs2 * |
| Frameshift and stop gained | 387_396delTTTGGCTAT         | Asn129Lysfs8 * |
| Stop gained           | 578C > A                    | Ser193 *       |
| Stop gained           | 655C > T                    | Gln219 *       |
| Stop gained           | 676G > T                    | Gln226 *       |
| Stop gained           | 723T > A                    | Tyr240 *       |
| Frameshift and stop gained | 751_752insA                 | Tyr251 *       |
| PilD                  |                             |                |
| Stop gained           | 532G > T                    | Gly178X        |

* indicates stop codon.

2.2. Characterizing the Role of pilD and dipA in F. tularensis Susceptibility to Resazurin

Almost all of the RZR LVS strains isolated possessed nonsynonymous mutations in multiple genes with some exceptions. The sole nonsynonymous mutation in RZR47 is in pilD while RZR46 contains a single nucleotide deletion resulting in loss in expression of the DipA protein (Table 2; data not shown). These findings suggest that loss of either pilD or dipA function may confer resazurin resistance with limited contributions/effects from other genes. To confirm the mutations in dipA and/or pilD were contributing to the reduced susceptibility of RZR strains to resazurin, we individually cloned wild-type copies of dipA and pilD into the Francisella vector pABST which contains the robust groE promoter of F. tularensis [11] and then introduced these new plasmids, pDipA and pPilD, into RZR46 and RZR47, respectively. Then, we tested the sensitivity of these strains to resazurin. We hypothesized that restoring expression of DipA and/or PilD in these RZR strains would alter their resistance phenotype. RZR46 and RZR47 containing pABST vector alone served as controls. The resazurin MICs for RZR46/pABST and RZR47/pABST were two-fold higher than the MIC for wild-type LVS (Table 3). Introduction of the pABST vector into the RZR strains did not alter their susceptibility to resazurin (data not shown). Complementation of RZR46 with dipA restored resazurin sensitivity back to wild-type with both RZR46/pDipA and LVS having MICs of 5.5 µg/mL (Table 3). In contrast, RZR47 containing the pilD expression construct has the same resazurin MIC as the vector control (Table 3). These data confirm a role for dipA, but not pilD, in F. tularensis LVS susceptibility to resazurin.

Table 3. Resazurin MIC for dipA and pilD complemented F. tularensis resazurin-resistant strains.

| Strain            | MIC (µg/mL) |
|-------------------|-------------|
| LVS               | 5.5         |
| Rzr 46/pABST      | 11          |
| Rzr 47/pABST      | 11          |
| Rzr 46/pDipA      | 5.5         |
| Rzr 47/pPilD      | 11          |

1 MICs are mode values from at least six independent determinations.

To individually investigate the role of dipA and pilD in resazurin susceptibility in a wild-type background, we generated a pilD disruption mutant (FTL_0959d) and a dipA
deletion mutant (ΔdipA) in *F. tularensis* LVS. The MICs of both FTL_0959d and ΔdipA were two-fold higher than that of wild-type LVS and comparable to the MICs determined for the spontaneous resazurin-resistant mutants RZR46 and RZR47 (Tables 3 and 4). We next sought to evaluate the bactericidal activity of resazurin against FTL_0959d and ΔdipA over time. Treatment with resazurin resulted in a significant reduction in viable bacteria after 24 h compared to untreated controls for all strains tested (Figure 1). However, significantly more FTL_0959d and ΔdipA bacteria were recovered 24 h post resazurin treatment compared to wild-type LVS (Figure 1). These data suggest that neither DipA nor PilD are targets of resazurin, but might be involved in the uptake and metabolism of this compound by *F. tularensis* LVS.

Table 4. MIC of resazurin for dipA and pilD *F. tularensis* LVS mutants.

| Strain     | MIC (µg/mL) 1 |
|------------|--------------|
| LVS        | 5.5          |
| ΔdipA      | 11           |
| FTL_0959d  | 11           |

1 MICs are mode values from at least three independent determinations.

![Figure 1](image.png)

**Figure 1.** Reduced killing of FTL_0959d and ΔdipA by resazurin compared to wild-type LVS. Bacteria were cultivated in tryptic soy broth supplemented with 0.1% cysteine HCl (TSBc) in the presence or absence of resazurin (Rz, 1.375 µg/mL) for 24 h. Cultures were then diluted and plated to determine the number of viable *F. tularensis* LVS bacteria 24 h post inoculation. Data shown are mean ± SEM from three individual experiments. The limit of detection was 100 CFU per ml. Statistically significant differences in growth post-inoculation were determined by two-way ANOVA followed by Tukey’s multiple comparisons test (***, p < 0.001 comparing +Rz to –Rz for each strain; $$$, p < 0.001 comparing FTL_0959d and ΔdipA to LVS 24 h. post Rz treatment).**

3. Discussion

The clinical threat posed by antibiotic resistant bacterial infections highlights the need to identify and apply novel antimicrobial therapies [2]. Resazurin exhibits antibacterial activity against *F. tularensis* and *N. gonorrhoeae*, but its mode of action has not been defined [9,10]. Here, we screened for resazurin-resistant mutants of *F. tularensis* LVS to identify genetic determinants of resazurin susceptibility. Whole genome sequencing of RZR isolates identified nonsynonymous mutations in ten different protein-coding genes. None of the genes identified in this screen were previously described to play a role in *F. tularensis* resistance to other clinically relevant antibiotics such as aminoglycosides, tetracyclines and fluoroquinolones [12,13]. Therefore, these data suggest resazurin has a unique mechanism of action.

In particular, two genes, dipA and pilD, were mutated in the majority of the RZR LVS clones isolated and sequenced. Complementation of RZR46 with dipA restored sensitivity to resazurin comparable to wild-type LVS while expression of pilD in RZR47 did not.
However, both a laboratory generated pilD disruption mutant and dipA deletion mutant had higher MICs compared to wild-type LVS similar to the spontaneous RZR mutants. The failure to restore resazurin sensitivity in RZR47 upon complementation with wild-type pilD may be due to a dominant negative effect of the original pilD mutation or another intergenic/undetected variant in RZR47 may be contributing to the resazurin resistance. Regardless, less killing of FTL_0959d and ΔdipA was observed over 24 h following resazurin treatment compared to wild-type LVS confirming a role for both dipA and pilD in resazurin susceptibility.

DipA is a 353 amino acid protein predicted to form a surface complex with other outer membrane proteins to facilitate translocation of virulence factors that interact with host cells [14]. Most of the dipA mutations characterized in this study occurred within the Sel1-like repeat domains (amino acids 95–170 and 192–263) which are known to be required for the biological function of DipA [14]. These structural domains provide a scaffold for protein–protein interactions [15]. DipA has been shown to associate with FopA, a F. tularensis outer membrane protein with noted homology to the OmpA porin [14]. OmpA has been shown to play a role in antibiotic resistance in other Gram-negative pathogens including Escherichia coli and Acinetobacter baumannii [16,17]. Given the correlation between DipA mutations and resazurin resistance in this study, it is possible that DipA plays a role in the stability or function of FopA allowing for uptake of resazurin. Without functional DipA, less resazurin may be taken up by F. tularensis LVS resulting in increased resistance to resazurin. Interestingly, none of the resazurin resistant strains isolated and sequenced in this study contained mutations in the LVS gene encoding FopA. The role of DipA and FopA in uptake of resazurin by F. tularensis is currently being investigated.

The PilD protein was also shown to contribute to F. tularensis susceptibility to resazurin. PilD is an inner membrane peptidase responsible for processing major and minor (pseudo) pilins involved in the formation of Type IV pili and assembly of a Type II protein secretion system [18,19]. In P. aeruginosa, PilD has also been shown to play a role in the export of select enzymes including alkaline phosphatase, phospholipase C, elastase, and exotoxin A [20]. Although the exact function of PilD in F. tularensis has not been fully investigated and defined, it is possible PilD may play a role in the processing and/or export of a protein that is a target of resazurin. Mutation of pilD would thus affect processing or export of the antibiotic target rendering F. tularensis less susceptible to resazurin. The exact role PilD plays in F. tularensis susceptibility to resazurin is under further investigation.

As F. tularensis is not the only bacterium susceptible to resazurin, we wondered whether pilD (FTL_0959) and dipA (FTL_1306) homologs were present in Neisseria and played similar roles as described here. A BLAST search [21] against the National Center for Biotechnology Information database of non-redundant protein sequences identified an A24 family peptidase (WP_003689814.1) and a SEL1-like repeat protein (MBS5742101.1) in Neisseria that were only 43% and 26% identical to F. tularensis PilD and DipA, respectively. The low homology between these proteins suggests that PilD and DipA have unique roles in F. tularensis susceptibility to resazurin. It also remains unknown whether DipA and PilD function in the same pathway to mediate F. tularensis killing by resazurin. The proposed function of DipA in transport and PilD in pilin processing suggests that they function separately from one another, but the relationship between DipA and PilD in mediating susceptibility to resazurin is currently being explored. Overall, mutations in pilD and dipA failed to confer complete resistance to resazurin. The growth of both FTL_0959d and ΔdipA was still inhibited by resazurin and the MICs for these mutants were only two-fold higher than wild-type LVS. An alternative method to identify potential antibiotic targets from the one used in this study is high-throughput transposon sequencing (Tn-Seq) [22–24]. In this approach, a library of LVS transposon mutants would be generated and screened for resazurin resistance [25]. Then, next-generation sequencing of the transposon insertion would be performed and the insertion sites would be mapped to the LVS genome. Further understanding of resazurin’s mode of action and resistance mechanisms will help guide the
development of resazurin derivatives with more potent activity as well as new therapeutic strategies to combat *Francisella* infections.

4. Materials and Methods

4.1. Bacterial Strains and Growth Conditions

Bacterial strains used in this study are listed in Table 5. For cultivation of *F. tularensis* LVS strains, frozen stock cultures were plated on chocolate II agar and incubated at 37 °C with 5% CO₂ for 2–4 days. These bacteria were then used to inoculate TSBc (trypticase soy broth (BD Biosciences) containing 0.1% l-cysteine hydrochloride monohydrate (Fisher)). *Escherichia coli* 5-α (New England Biolabs) bacteria cultivated on LB agar were used to inoculate LB broth. All broth cultures were incubated at 37 °C with agitation. When required, kanamycin (35 µg/mL for *E. coli*; 10 µg/mL for *F. tularensis*) and hygromycin (250 µg/mL) were supplemented into the media.

Table 5. Description of strains, plasmids, and primers used in this study.

| Plasmid, Primer, or Strain Description or Sequence | Source or Reference |
|--------------------------------------------------|---------------------|
| *F. tularensis* strains                          |                     |
| LVS                                              | *F. tularensis* subsp. holarctica live vaccine strain |
| RZR46 Spontaneous resazurin-resistant LVS mutant containing deletion of single thymine residue at position 2 in dipA | This study |
| RZR47 Spontaneous resazurin-resistant LVS mutant containing 532G > T substitution in pilD | This study |
| FTL_0959d LVS pilD disruption mutant             | This study |
| E. coli strains                                   |                     |
| DHA5    fhuA2 Δ(argF-lacZ)U169 phoA gltV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 | NEB ¹ |
| Plasmids                                         |                     |
| pABST pFNLTP8 with *F. tularensis* LVS groE promoter | [11] |
| pDipA pABST containing *dipA* under control of groE promoter | This study |
| pPilD pABST containing *dipA* under control of groE promoter | This study |
| pJH1 pMO225 with the I-SceI restriction site | [26] |
| pGUTS pGR with I-SceI under the control of FGRp | This study |
| pJH1-0959d with the left and right 500-bp flanking regions of *dipA* cloned into the PstI-5phl site of pJH1 | This study |
| Primers                                          |                     |
| 1F_dipA 5'-CATGCTGCAGGTAGTGTGTTGATCTTTGTATAGCAG-3' | IDT ² |
| 2R_dipA 5'-ATAATAAGCTGGAGGCAACAGAGAATTATAAAAAATTAGCTTTCATCTATTTCCCTTG-3' | This study |
| 3F_dipA 5'-ACCCGCTGACGTACGTAACGTTTATGTTTACATCGAGCGAAGCGGCCAG-3' | This study |
| 4R_dipA 5'-CATGCCATGCCATACCCACTTTAAGACTACTTGCG-3' | This study |
| F_0959d 5'-CATGGGATCCGGGATTGATAAGCAACAATCTCCAC-3' | IDT |
| R_0959d 5'-CATTGCATGCCAAGCCCTCTTTACCTTGAAG-3' | This study |
| dipA_F 5'-CATGAAATTC GTGACGCCCTGTATTTTGTATGCAGG-3' | This study |
| dipA_R 5'-CATGCTAGCGGTCATAAAATGCTTGATGATTTTGCAGG-3' | This study |
| pilD_F 5'-ATCCGAATTCTATTTTGATATAATATCGAGGGCAAAATAAC-3' | This study |
| pilD_R 5'-ATCCACATATGTTATACGATATAATCTTTGATTGCAAG-3' | This study |
| pJH1_conf 5'-CTTAGATTTAAATCTGATACGCTGAAAATC-3' | This study |

¹ NEB—New England Biotechnologies. ² IDT—Integrated DNA Technologies.

4.2. Selection of Resazurin-Resistant (RZR) LVS Mutants and Whole Genome Sequencing

Mutants resistant to resazurin were obtained by plating suspensions containing approximately 5 × 10⁸ CFU of *F. tularensis* LVS bacteria on chocolate II agar supplemented with 11 µg/mL resazurin sodium salt (Acros Organics, dissolved in water) [9]. This concentration of resazurin is ten-fold higher than the previously determined minimal inhibitory concentration (MIC) of resazurin [9]. Colonies that formed on plates containing 11 µg/mL resazurin were then replica-plated onto 22 µg/mL resazurin. Forty-six resazurin-resistant (RZR) LVS clones that grew in the presence of 22 µg/mL resazurin were selected for further
analysis. Genomic DNA was isolated using the Bacterial Genomic DNA Isolation Kit (Norgen Biotek Corp., Thorold, ON, Canada) per the manufacturer's instructions. Sequencing libraries were prepared using Nextera XT DNA Library Preparation Kits (Illumina, San Diego, CA, USA) and individual libraries were indexed with barcodes using Nextera XT v2 Index Kits (Illumina, San Diego, CA, USA) in the Marshall University (MU) Genomics Core Facility. Library quality and size distribution was assessed on an Agilent Bioanalyzer equipped with High Sensitivity DNA Chips. Libraries were quantitated by Qubit fluorimetry. High throughput sequencing (2 × 100 bp paired-end) was performed on an Illumina HiSeq1500 in Rapid Run mode in the Genomics Core. This approach allowed for approximately 150× coverage of each individual bacterial genome.

Sequencing reads were trimmed to remove Illumina adapters and low quality base calls using Trimmomatic version 0.36 [27]. Trimmed reads were aligned to the *Francisella tularensis* reference genome (NCBI accession number AM23362.1) using BWA version 0.7.12 [28] and sorted and indexed using picard tools version 2.9.4. Variant calling was performed following the GATK version 3.8.0 pipeline [29]. Briefly, duplicates were marked with the MarkDuplicates tool and per-sample variants identified using HaplotypeCaller. Variants were then called across the entire sample set using the GenotypeGVCFs tool with the sample-ploidy option set to one. Variant calls with quality score below 20 were filtered out using the VariantFiltering tool. Variants were exported to tab-delimited format using VariantsToTable. After the conclusion of these GATK pipeline steps, variants were annotated to determine their effects on the protein sequence using snpEff version 4.3q [30].

4.3. Construction of dipA and pilD Complemented Strains and Mutants

Primer and plasmids used in this study are listed in Table 5. To complement RZR LVS mutants with either wild-type *dipA* or *pilD*, *F. tularensis* LVS chromosomal DNA extracted from stationary-phase broth cultures using the Bacterial Genomic DNA Isolation Kit (Norgen Biotek Corp.) served as a template for amplification of *dipA* (FTL_1306) and *pilD* (FTL_0959). Primer pairs dipA_F/dipA_R and pilD_F/pilD_R were used to PCR-amplify *dipA* and *pilD*, respectively. The *dipA* amplicon was cloned into the EcoRI-NheI site of pABST [24] to generate the plasmid, pDipA. The pilD amplicon was cloned into the EcoRI-NdeI site of pABST to create the plasmid, pPilD. Both pDipA and pPilD were introduced into select *F. tularensis* LVS resazurin-resistant mutant strains by electroporation and selection on chocolate II agar supplemented with 10 µg/mL kanamycin.

The *pilD* disruption mutant (FTL_0959d) was generated using an unstable, integrating suicide vector, pJH1, as previously reported [31,32]. An internal 470 base pair region of FTL_0959 (*pilD*) was amplified by PCR using the primers F_0959d and R_0959d. This amplicon was digested with BamHI and SphI and then cloned into pJH1 that had been digested with these same enzymes, which produced pJH1-0959d. This disruption construct was mobilized into *F. tularensis* LVS by triparental mating [31]. Hygromycin-resistant colonies were screened by PCR using the primers pJH1-conf and 1F_pilD which are specific for the vector-portion of pJH1-FTL_0959 and pilD respectively, to confirm disruption of the pilD gene.

A *F. tularensis* LVS *dipA* (FTL_1306) deletion mutant was generated using pJH1 and the I-SceI endonuclease as described previously [26]. To begin, the *dipA* deletion construct pJH1-ΔdipA was generated using splicing by overlap-extension PCR. Regions (~500 bp) upstream and downstream of the *dipA* sequence targeted for deletion were amplified by PCR using the primers F_0959d and R_0959d. This amplicon was digested with BamHI and SphI and then ligated into pJH1 that had been digested with these same enzymes, which produced pJH1-0959d. This disruption construct was mobilized into *F. tularensis* LVS by triparental mating [31]. Hygromycin-resistant colonies were screened by PCR using the primers pJH1-conf and 1F_pilD which are specific for the vector-portion of pJH1-FTL_0959 and pilD respectively, to confirm disruption of the pilD gene.
tant to kanamycin were screened by PCR for deletion of dipA using primers 1F_dipA and 4R_dipA. To cure pGUTS, the F. tularensis ΔdipA strains were repeatedly sub-cultured in TSBc, diluted, and plated to a density of 100 to 300 colony forming units CFU per chocolate II agar plate. Plates were incubated for at least 3 days at 37 °C, 5% CO2 and colonies that formed were replica plated onto chocolate II agar supplemented with and without 10 µg/mL kanamycin to select against colonies harboring pGUTS. Those colonies sensitive to kanamycin were isolated and again tested for sensitivity to this antibiotic. The resulting LVS strain was named ΔdipA. Western blot analysis using an anti-DipA antibody [14] confirmed loss in expression of the DipA protein in LVS ΔdipA (data not shown).

4.4. Agar Dilution Susceptibility Testing

Minimum inhibitory concentrations (MICs) were determined by the agar dilution method using chocolate II agar according to CLSI guidelines [33]. Briefly, F. tularensis LVS bacteria were cultivated overnight in TSBc, diluted to an OD600 of 0.3 (approximately 5 × 10^8 CFU/mL), and then diluted to 1 × 10^6 CFU/mL. Ten microliters of this suspension (1 × 10^4 CFU) were plated onto chocolate II agar containing a series of two-fold dilutions of resazurin. Following incubation (37 °C with 5% CO2 for 48–72 h), the MIC reported for each F. tularensis strain was the lowest concentration of resazurin that completely inhibited the growth of bacteria on the agar plate. No strain differed by more than one dilution in 3–5 tests.

4.5. Time Kill Assays

F. tularensis LVS overnight broth cultures were used to inoculate TSBc containing 1.375 µg/mL resazurin. Immediately following inoculation and 24 h later, cultures were serially diluted and plated onto chocolate II agar. Plates were incubated at 37 °C, 5% CO2 and individual colonies were enumerated. The limit of detection was 100 CFU/mL.

4.6. Statistical Analyses

Data were analyzed for significant differences using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA). The statistical tests are indicated in the figure legend.

**Author Contributions:** Conceptualization, D.M.S.; methodology, J.H., D.A.P., J.D. and D.M.S.; resources, K.S., E.J.B., S.C.M., M.W., E.Y., J.P., D.W., J.H., D.A.P., J.D. and D.M.S.; data curation, D.A.P., J.D. and D.M.S.; writing—original draft preparation, K.S. and D.M.S.; writing—review and editing, K.S., E.J.B., S.C.M., M.W., E.Y., J.P., D.W., J.R., J.H., D.A.P., J.D. and D.M.S.; visualization, K.S., E.J.B., S.C.M., M.W., J.P., D.W., J.R. and D.M.S.; supervision, D.M.S.; project administration, D.M.S.; funding acquisition, D.A.P., J.H. and D.M.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by a pilot grant from the West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE) program which is supported by a grant from the National Institute of General Medical Sciences of the National Institutes of Health (P20GM103434). Whole genome sequencing was carried out by the Marshall University Genomics Core Facility, which is supported by the WV-INBRE grant (P20GM103434), the COBRE ACCORD grant (1P20GM121299) and the West Virginia Clinical and Translational Science Institute (WV-CTSI) grant (2U54GM104942). The Research Resource ID (RRID) citation for the MU Genomics Core is RRID:SCR_018885. In addition, a portion of this work was funded by the National Heart Lung and Blood Institute of the National Institutes of Health (1R15HL147135).

**Data Availability Statement:** All sequencing data have been submitted to the Sequence Read Archive at the National Center for Biotechnology Information (NCBI) and are accessible via project number PRJNA748943.

**Acknowledgments:** The authors thank Karen Elkins for providing LVS and Jean Celli for the rat anti-FTT0369c antibody to detect expression of DipA.

**Conflicts of Interest:** The authors acknowledge that Joseph Horzempa has been awarded a patent (US20150258103A1) on the antimicrobial activity of the compounds used in this manuscript. However,
the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Centers for Disease Control and Prevention. *Antibiotic Resistance Threats in the United States*, 2019; Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019.

2. Ventola, C.L. The antibiotic resistance crisis: Causes and threats. *Phys. Ther. J.* 2015, 40, 277–283.

3. Plackett, B. Why big pharma has abandoned antibiotics. *Nature* 2020, 586, S50–S52. [CrossRef] [PubMed]

4. Hutchings, M.; Truman, A.; Wilkinson, B. Antibiotics: Past, present and future. *Curr. Opin. Microbiol.* 2019, 51, 72–80. [CrossRef] [PubMed]

5. Sridhar, B.T.; Girish, K.; Channu, B.C.; Thimmaiah, K.N.; Kumara, M.N. Antibacterial activity of phenoxazine derivatives. *J. Chem. Pharm. Res.* 2015, 7, 1074–1079.

6. Onoabedje, E.A.; Ayogu, J.I.; Odoh, A.S. Recent Development in Applications of Synthetic Phenoxazines and Their Related Congeners: A Mini-Review. *ChemistrySelect* 2020, 5, 8540–8556. [CrossRef]

7. Praveen, V.; Tripathi, C.K.M. Studies on the production of actinomycin-D by Streptomyces griseoruber—A novel source. *Lett. Appl. Microbiol.* 2009, 49, 450–455. [CrossRef]

8. Wang, Q.; Zhang, Y.; Wang, M.; Tan, Y.; Hu, X.; He, H.; Xiao, C.; You, X.; Wang, Y.; Gan, M. Neo-actinomycins A and B, natural actinomycins bearing the 5H-oxazolo[4,5-b]phenoxazine chromophore, from the marine-derived *Streptomyces* sp. IMB094. *Sci. Rep.* 2017, 7, 3591. [CrossRef]

9. Schmitt, D.M.; O’Dee, D.M.; Cowan, B.N.; Birch, J.W.M.; Mazzella, L.K.; Nau, G.J.; Horzempa, J. The use of resazurin as a novel antimicrobial agent against Francisella tularensis. *Front. Cell. Infect. Microbiol.* 2013, 3, 93. [CrossRef]

10. Schmitt, D.M.; Connolly, K.L.; Jerse, A.E.; Detrick, M.S.; Horzempa, J. Antibacterial activity of resazurin-based compounds against *Neisseria gonorrhoeae* in vitro and in vivo. *Int. J. Antimicrob. Agents* 2016, 48, 367–372. [CrossRef]

11. Robinson, C.M.; Kobe, B.N.; Schmitt, D.M.; Phair, B.; Gilson, T.; Jung, J.-Y.; Roberts, L.; Liao, J.; Camerlengo, C.; Chang, B.; et al. Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against *Pseudomonas aeruginosa* infections. *Bioengineered* 2015, 6, 82–88. [CrossRef]

12. Biot, F.V.; Bachert, B.A.; Mlynék, K.D.; Toothman, R.G.; Koroleva, G.I.; Lovett, S.P.; Klimko, C.P.; Palacios, G.F.; Cote, C.K.; Ladner, J.T.; et al. Evolution of Antibiotic Resistance in Surrogates of Francisella tularensis (LVS and Francisella novicida): Effects on Biofilm Formation and Fitness. *Front. Microbiol.* 2020, 11, 593542. [CrossRef] [PubMed]

13. Kassinger, S.J.; Van Hoek, M.L. Genetic Determinants of Antibiotic Resistance in Francisella. *Front. Microbiol.* 2021, 12, 644855. [CrossRef]

14. Chong, A.; Child, R.; Wehrly, T.D.; Rockx-Brouwer, D.; Qin, A.; Mann, B.J.; Celli, J. Structure-Function Analysis of DipA, a Francisella tularensis Virulence Factor Required for Intracellular Replication. *PLOS ONE* 2013, 8, e67965. [CrossRef]

15. Mittl, P.R.E.; Schneider-Brachert, W. Sell1-like repeat proteins in signal transduction. *Cell. Signal.* 2007, 19, 20–31. [CrossRef]

16. Smani, Y.; Farge, A.; Roca, I.; Sanchez-Encinales, V.; Vila, J.; Pachón, J. Role of OmpA in the Multidrug Resistance Phenotype of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2014, 58, 1806–1808. [CrossRef] [PubMed]

17. Viveiros, M.; Dupont, M.; Rodrigues, L.; Couto, I.; Davin-Regli, A. Antibiotic Stress, Genetic Response and Altered Permeability of *E. coli*. *PLOS ONE* 2007, 2, e365. [CrossRef] [PubMed]

18. Forsberg, Å.; Guina, T. Type II Secretion and Type IV Pili of Francisella. *Ann. N. Y. Acad. Sci.* 2007, 1105, 187–201. [CrossRef]

19. Nguyen, Y.; Harvey, H.; Sugiman-Marangos, S.; Bell, S.D.; Buenosuceso, R.N.C.; Junop, M.S.; Burrows, L.L. Structural and Functional Studies of the Pseudomonas aeruginosa Minor Pilin, PilP. *Pfie. J. Biol. Chem.* 2015, 290, 26856. [CrossRef]

20. Strom, M.S.; Nunn, D.; Lory, S. Multiple roles of the pilus biogenesis protein PilD: Involvement of PilD in excretion of enzymes from *Pseudomonas aeruginosa*. *J. Bacteriology* 1991, 173, 1175–1180. [CrossRef]

21. Altschul, S.F.; Madden, T.L.; Schäffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. *Nucleic Acids Res.* 1997, 25, 3389–3402. [CrossRef]

22. Willcocks, S.; Huse, K.K.; Stabler, R.; Oyston, P.C.; Scott, A.; Atkins, H.S.; Wren, B.W. Genome-wide assessment of antimicrobial tolerance in Yersinia pseudotuberculosis under ciprofloxacin stress. *Microb. Genom.* 2019, 5, e000304. [CrossRef]

23. Gallagher, L.A.; Shendure, J.; Manoil, C. Genome-scale identification of resistance functions in *Pseudomonas aeruginosa* using Tn-seq. *MBio* 2011, 2, e00315-10. [CrossRef]

24. Vitale, A.; Pessi, G.; Urfer, M.; Locher, H.H.; Zerbe, K.; Obrecht, D.; Robinson, J.A.; Eberl, L. Identification of Genes Required for Resistance to Peptidomimetic Antibiotics by Transposon Sequencing. *Front. Microbiol.* 2020, 11, 1681. [CrossRef]

25. Schmitt, D.M.; O’Dee, D.M.; Horzempa, J.; Carlson, P.E., Jr.; Russo, B.C.; Bales, J.M.; Brown, M.J.; Nau, G.J. A Francisella tularensis live vaccine strain that improves stimulation of antigen-presenting cells does not enhance vaccine efficacy. *PLOS ONE* 2012, 7, e31172. [CrossRef]

26. Horzempa, J.; Shanks, R.M.Q.; Brown, M.J.; Russo, B.C.; O’Dee, D.M.; Nau, G.J. Utilization of an unstable plasmid and the I-SceI endonuclease to generate routine markerless deletion mutants in Francisella tularensis. *J. Microbiol. Methods* 2010, 80, 106–108. [CrossRef] [PubMed]

27. Bolger, A.M.; Lohse, M.; Usadel, B. Genome analysis Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 2014, 30, 2114–2120. [CrossRef] [PubMed]
28. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **2009**, *25*, 1754–1760. [CrossRef]

29. Van der Auwera, G.A.; Carneiro, M.O.; Hartl, C.; Poplin, R.; Del Angel, G.; Levy-Moonshine, A.; Jordan, T.; Shakir, K.; Roazen, D.; Thibault, J.; et al. From FastQ data to high confidence variant calls: The GenomeAnalysis Toolkit best practices pipeline. *Curr. Protoc. Bioinform.* **2013**, *43*, 11.10.1–11.10.33. [CrossRef]

30. Cingolani, P.; Platts, A.; Wang, L.L.; Coon, M.; Nguyen, T.; Wang, L.; Land, S.J.; Lu, X.; Ruden, D.M. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff SNPs in the genome of Drosophila melanogaster strain w^1118; iso-2; iso-3. *Fly* **2012**, *6*, 80–92. [CrossRef] [PubMed]

31. Horzempa, J.; Carlson, P.E., Jr.; O’Dee, D.M.; Shanks, R.M.Q.; Nau, G.J. Global transcriptional response to mammalian temperature provides new insight into *Francisella tularensis* pathogenesis. *BMC Microbiol.* **2008**, *8*, 172. [CrossRef]

32. Shanks, R.M.Q.; Caiazzo, N.C.; Hinsa, S.M.; Toutain, C.M.; O’Toole, G.A. Saccharomyces cerevisiae-based molecular tool kit for manipulation of genes from gram-negative bacteria. *Appl. Environ. Microbiol.* **2006**, *72*, 5027–5036. [CrossRef] [PubMed]

33. Clinical and Laboratory Standards Institute. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*, 12th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018.